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Essentials
• Fibrinogen prothrombin time-derived (FIBPT-d) behavior in anticoagulated patients is under studied.
• FIBPT-d method overestimates fibrinogen in rivaroxaban and low molecular weight heparin samples.
• Unfractionated heparin and dabigatran samples showed similar bias to the control group.
• Rabbit brain and human recombinant thromboplastin behavior was different in rivaroxaban samples.
Summary. Background:
The fibrinogen prothrombin timederived (FIBPT-d) method with photo-optical coagulometers is easy and economical. However, there are few reports on the behavior of this test on samples from patients anticoagulated with direct oral anticoagulants or low molecular weight heparin (LMWH [5] [6] [7] . It is important to remember that, in subjects with dysfibrinogenemia, this test may yield normal values [8] . The FIBPT-d method has been validated only in the normal population, so it should not be used in another clinical situation. There are few reports on the behavior of this test in patients anticoagulated with direct oral anticoagulants or low molecular weight heparin (LMWH) [3] [4] [5] [6] 8, 9] . The aim of this study was to compare fibrinogen concentration results obtained by the use of the the FIB C method and the FIBPT-d method with two thromboplastins of different origin in anticoagulated patients.
Materials and methods

Population
The study material comprised 295 consecutive samples from patients with normal PT and activated partial thromboplastin time prior to initiation anticoagulant treatment, including 99 receiving VKAs with an International Normalized Ratio (INR) of > 1.5 (all outpatients of anticoagulant clinics), 49 receiving unfractionated heparin (UFH) and 47 receiving LMWH with anti-activated factor X (FXa) activity of > 0.1 U mL
À1
, 50 receiving rivaroxaban and 50 receiving dabigatran (all outpatients), and 100 normal controls (NCs). Population characteristics and anticoagulation intensity are summarized in Table 1 . Approximately 75% of patients were taking oral anticoagulants (VKAs, rivaroxaban, or dabigatran) for atrial fibrillation, and 25% were taking them for venous thromboembolism treatment. Patients received LMWH for venous thromboembolism, and 35% of these were inpatients. Patients received UFH for acute coronary syndrome (61%) and venous thromboembolism (39%), and all of these were inpatients. 
Methods
FIB C is the test to measure Fibrinogen by the
Results and discussion
Patient characteristics are summarized in Table 1 . There were no statistical differences in sex, age and fibrinogen levels, measured by Clauss method, between groups. Table 2 shows the percentage bias between the FIB C method and the FIBPT-d method in all groups with each thromboplastin used. For every type of sample investigated, the Pearson correlation coefficients between the the FIB C method and the FIBPT-d method with both thromboplastins were > 0.88, but Bland-Altman analysis showed that there was a positive bias (P < 0.001) for the FIBPT-d method in both NC ( Figs 1A and 2A) or anticoagulated patient samples. However, this bias was significantly higher than that in NC samples for rivaroxaban and VKA samples with HS (Fig. 1B,C) . On the other hand, LMWH samples showed a higher bias than NC samples with both thromboplastins used ( Figs 1D and  2D ). When the results of samples containing UFH or dabigatran were analyzed, the biases with both thromboplastin also existed, but were not significantly different from that observed in the NC group, and were acceptable when a total error of 20% was allowed (CLIA quality requirement) [10] (see Fig. 1E ,F for HS, and Several studies have compared the FIB C and FIBPT-d methods in the healthy population, and showed a positive bias for the FIBPT-d method when fibrinogen levels were > 4 g L À1 [3] [4] [5] [6] . In this study, the biases observed in the NC group (without exclusion of outliers) when rabbit brain thromboplastin was used were 13.7% and 12%, when all samples were considered, or only those with fibrinogen levels of < 4 g L À1 were considered, respectively.
When human recombinant thromboplastin was used, the bias was 19% with all samples and 16.9% with those with fibrinogen levels of < 4 g L
À1
. After exclusion of outliers (three samples not icteric and without hemolysis that showed a high positive bias with both thromboplastins), the bias was lower. Although our results show a slightly higher bias than that reported by other authors for fibrinogen levels between 2 g L À1 and 4 g L
, this bias is not clinically significant in normal individuals. The difference between our bias and the one reported by other authors could be attributable to the use of different thromboplastins and coagulation detection systems in FBGPT-d assays. In agreement with other reports, our results show that the FBGPT-d method is useful if fibrinogen levels are normal, or if it is used in patients without bleeding.
This test has not been validated for the diagnosis of dysfibrinogenemia. It has been suggested that the FIBPTd method should not be used as the first test in bleeding disorder screening, because it could give normal results for some dysfibrinogenemias [7] .
A lack of correlation between both fibrinogen methods was shown when the prothrombin time was prolonged, such as in patients receiving VKA therapy. We and others found~30% positive bias of the FIBPT-d method in dicumarinic-anticoagulated patient samples [3, 6] .
Our results show that, when patients were anticoagulated with drugs with indirect or direct anti-activated FII (FIIa) activity, such as UFH or dabigatran, the FIBPT-d assay results obtained with both thromboplastins were close to those obtained with the Clauss method. This agrees with results previously published for UFH [6] and dabigatran [8] . Using dabigatran-spiked samples, Van Blerk et al. showed that FIBPT-d assay results obtained on the ACL TOP with Recombiplastin 2G were similar to those obtained with the Clauss method in a nationwide Belgian survey [8] . However, for patients anticoagulated with drugs with either direct or indirect anti-FXa activity, such as rivaroxaban or LMWH, we found that the FIBPT-d method has a positive bias as compared with the FIB C method (Table 2 ; Figs 1C,D and 2D) . Mani et al. reported fibrinogen derived values using four different thromboplastin reagents on ex vivo samples from patients undergoing major orthopedic surgery at various time points after rivaroxaban (10 mg daily) administration. After surgery, when fibrinogen levels were elevated, results at 2 h (peak) but not at 12 h (through) after administration were significantly overestimated as compared with previous drug administration with rabbit brain thromboplastin (Neoplastin C Plus). A similar tendency was found with one recombinant thromboplastin (Innovin), but not with human placenta-derived reagent. This agrees with our results, where only PT fibrinogen HS (rabbit brain) and not Recombiplastin gave significant overestimation of fibrinogen results in rivaroxaban samples (Table 2 ). Although they did not directly compare the FIBPT-d method with the FIB C method, it is clear CI, confidence interval; HS; LMWH, low molecular weight heparin; RP. *P < 0.0001, patients receiving anticoagulation versus normal control plasmas. †P < 0.0001, HS versus RP thromboplastins in vitamin K antagonist-anticoagulated patients' plasmas. ‡P < 0.0001, HS versus RP thromboplastins in rivaroxaban-anticoagulated patients' plasmas. .00
-20.00 that, for Neoplastin C Plus, Innovin, and Recombiplastin, but not for Thromborel, FIBPT-d assay results were significantly higher than FIB C assay results at 2 h after administration. [9] . It is important to note that the behavior of the FIBPTd method is different between samples containing anti-FIIa (UFH and dabigatran) and those containing anti-FXa (LMWH and rivaroxaban) anticoagulants. It could be hypothesized that these differences may be attributable to the lower rate of thrombin generation caused by anti-FXa drugs, in contrast to anti-FIIa drugs, which inhibit the generated thrombin, but do not affect the rate of thrombin generation.
Several potential sources of discrepancy between the FIB C and FIBPT-d methods have been described, so it is important for result extrapolation to be performed in well-characterized patient groups. It is interesting to note that not all thromboplastins behave similarly in each group of patients, as Mani et al. reported for rivaroxaban; also, our study showed a greater bias when rabbit brain thromboplastin was used than when human recombinant thromboplastin was used in VKA and rivaroxaban patient samples, but not in LMWH patient samples (Table 2) . Therefore, both the type of anticoagulant treatment and the thromboplastin origin are factors that affect FIBPT-d assay results. Moreover, these effects could not be extrapolated to other thromboplastins in other coagulometer platforms for anticoagulated patients. It is important to keep in mind that the mathematical algorithm has been validated only in the normal population, and thus FIBPT-d methods should not be used for anticoagulated patient samples.
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